Facts and artefacts of coagulation assays for factor Xa inhibitors.

@article{Haas2010FactsAA,
  title={Facts and artefacts of coagulation assays for factor Xa inhibitors.},
  author={Sylvia Haas},
  journal={Thrombosis and haemostasis},
  year={2010},
  volume={103 4},
  pages={686-8}
}
Direct factor Xa inhibitors are among the compounds at the forefront of clinical development for the prevention and treatment of thromboembolic disorders; of these, rivaroxaban, apixaban and edoxaban (DU-176b) are in the most advanced stages of development. Rivaroxaban is approved in several countries for the prevention of venous thromboembolism (VTE) after elective hip or knee arthroplasty, and trials are ongoing for other indications. Apixaban and edoxaban are undergoing clinical development… CONTINUE READING
11 Citations
17 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

on behalf of the Einstein investigators. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The Einstein-Extension study

  • HR Buller
  • http://ash.confex.com/
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…